+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Antihypertensive Action of Calcium Blockade in Hypertensive Patients with Chronic Renal Disease

      , ,


      S. Karger AG

      Ca2+ blockade, Hypertension, Chronic renal disease

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          The concentration of ionic calcium (Ca<sup>2+</sup> in the smooth muscular cells of the resistance vessels is a determining factor of their contraction. It depends on the influx of Ca<sup>2+</sup> to the interior of the cells through the calcium channels in the sarcolemma. The effect of a specific Ca<sup>2+</sup>-channel blocking agent – nifedipine – on arterial hypertension in a group of 18 patients with chronic renal hypertension is reported in this study. The combination of nifedipine and propranolol in the control of hypertension in 6 of these patients in a long-term follow-up was also studied. It was concluded: (1) Ca<sup>2+</sup> blockade had a rapid and powerful antihypertensive effect in all patients; (2) the antihypertensive effect was higher with high initial blood pressure levels; this fact was especially evident and appeared particularly useful in hypertensive emergencies; (3) in some patients, the action of nifedipine was dose-dependent; (4) nifedipine had a short-lived action; (5) the combination nifedipine-propranolol was efficient in the long-term control of hypertension.

          Related collections

          Author and article information

          S. Karger AG
          04 December 2008
          : 41
          : 4
          : 314-319
          Nephrology Department, Hospital Curry Cabral, Lisbon, Portugal
          183607 Nephron 1985;41:314–319
          © 1985 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 6
          Original Paper

          Cardiovascular Medicine, Nephrology

          Ca2+ blockade, Chronic renal disease, Hypertension


          Comment on this article